-
 IGNT-Ingen Technologies, Inc.
Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
-
IGNT-Ingen Technologies, Inc.
IGNT has just announced paying off about 30% of its debt over the past 60 days, with plans to pay-off all debt by the end of this first quarter.
IGNT accumulated debt during 2008 due to the economy pressures in the United States and costs associated in the marketing and sale of their new Oxyview respiratory product.
During the IGNT's fourth quarter (March-May 31, 2009) the company paid off more than $200,000 in debt to creditors and vendors.
IGNT has implemented an aggressive program to reduce debt 100% by the end of August 2009, and commence deliveries of the new Oxyview-Cannula in June 2009.
"This program improves shareholder value and provides a sound basis to launch our new respiratory products," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
-
IGNT news 6/8
Ingen Receives Good Response From National Advertisment in COPD Digest
On Monday June 8, 2009, 4:39 pm EDT
YUCAIPA, Calif., June 8, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Other OTC:IGNT.PK - News) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the company has received an increase in Oxyview orders and telephone orders from COPD patients and new distributor inquiries from the advertisement in the COPD Digest.
In March-2009 Ingen signed an insertion order with COPD Digest to run a national advertisement for the new Oxyview. COPD Digest is published by the COPD Foundation, with the support of -- and contributions from -- organizations representing the entire COPD community. Chronic Obstructive Pulmonary Disease (COPD) affects over 600 million people worldwide. Oxyview provides these patients with the ability to assure oxygen flow and equipment function.
``Since the ad was issued last week with over 160,000 circulations, there has been an increase with on-line orders through our website and PayPal, as well as telephone orders. The patients and new potential distributors are very pleased with the new Oxyview product,'' stated Chris Wirth, Chief Operations Officer.
About Oxyview:
Oxyview is a proprietary medical device with U.S.-issued patents that stands alone in an increasing patient home oxygen therapy market while there are 23 million patients diagnosed with chronic obstructive pulmonary disease (COPD) in the United States, according to the World Health Organization, and another 12 million patients that are undiagnosed in the US. COPD is the fifth leading cause of death in the US and there are 600 million COPD patients worldwide where in most cases, COPD is either the first or second leading cause of death in other countries. The majority of COPD patients require continued home oxygen therapy, which includes all of the required equipment supplied by the home (DME) provider. With the new regulations for oxygen reimbursement in the US, the home (DME) providers need to cut costs to stay in business. Oxyview provides a substantial savings as a result of decreasing the number of service calls for the home (DME) provider. Oxyview is a pneumatic metering device that displays oxygen flow near the patient. The Oxyview flow meter easily and quickly installs on to the oxygen tubing nearest the patient where oxygen flow matters the most. Without the Oxyview, patients cannot confirm oxygen flow, and as a result there is an increase in anxiety and the patient calls the home (DME) provider with concerns. Oxyview also allows the home (DME) provider to trouble-shoot other equipment problems over the telephone which eliminates an on-site visit with the patient. More important, the Oxyview provides the patient with more assurance that they are receiving adequate and prescribed oxygen flow. The Oxyview cost less than a single service call.
Ingen Technologies,Inc. - Home
The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.
Welcome to the COPD Digest!
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Contact:
Ingen Technologies, Inc.
Chris Wirth
909-790-7180
info@ingen-tech.com
Ingen Technologies,Inc. - Home
I am not a registered broker and my signatures are of my own opinion. Make your buys and sells as you see fit, never invest more than you can afford to loose.
-
IGNT Chart
Congrats to all who took advantage of the alert on IGNT. Support is the 20 MA line of .00215 resistance is .0047 and .007
All my signatures are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on.
-
Ignt
IGNT.PK Ingen Technologies, Inc.
IGNT had a Super good trading day, closing with a gain of 59% at .0035. Volume today was well over 310 million which is 4X the 10 day average.
There was also a press release come out after the close that could indicate more attention coming to the stock tomorrow.
I strongly advise keeping IGNT on a close watch, this could be just the beginning.
News from today after close:
“Ingen Receives Good Response From National Advertisment in COPD Digest”Link::
Ingen Receives Good Response From National Advertisment in COPD Digest - Yahoo! Finance
I am not a registered broker and my signatures are of my own opinion. Make your buys and sells as you see fit, never invest more than you can afford to loose.
-
Re ignt
IGNT has had a very nice past couple of days congrats to all who took advantage of the alert up 320% today on $3888234 total dollar volume.
All my signatures are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on.
-
IGNT News
YUCAIPA, Calif., June 10, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the company has commenced ISO 13485 staff training this week with the Emergo Group.
The company has signed contracts with the Austin-Texas based Emergo Group to prepare, train and coordinate all International Standard Organization (ISO) 13485 certifications to market and sell Oxyview in China, Japan, Canada and the European Community. In addition to the ISO certification requirement, the contracts also include the CE Mark required to sell Oxyview in Europe.
The training and document specialist with the Emergo Group, Cheryl Fisher, has been training the Ingen management and staff on ISO certification and document requirement procedures. The ISO certification process will take approximately 3-6 months. ISO is a network of the national standards institutes of 161 countries, one member per country, with a Central Secretariat in Geneva, Switzerland, that coordinates the system. ISO is a non-governmental organization that forms a bridge between the public and private sectors. On the one hand, many of its member institutes are part of the governmental structure of their countries, or are mandated by their government. On the other hand, other members have their roots uniquely in the private sector, having been set up by national partnerships of industry associations. Therefore, ISO enables a consensus to be reached on solutions that meet both the requirements of business and the broader needs of society.
"Ingen has invested tens of thousands of dollars with the Emergo Group to insure ISO 13485 certification in countries that have a strong interest and large revenue potential for our Oxyview product, inclusive of our new Oxyview-Cannula product being introduced in the next week," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
About Oxyview:
Oxyview is a proprietary medical device with U.S. issued patents that stands alone in an increasing patient home oxygen therapy market while there are 23 million patients diagnosed with chronic obstructive pulmonary disease (COPD) in the United States, according to the World Health Organization, and another 12 million patients that are undiagnosed in the U.S. COPD is the fifth leading cause of death in the U.S. and there are 600 million COPD patients worldwide where in most cases, COPD is either the first or second leading cause of death in other countries. The majority of COPD patients require continued home oxygen therapy, which includes all of the required equipment supplied by the home (DME) provider. With the new regulations for oxygen reimbursement in the U.S., the home (DME) providers need to cut costs to stay in business. Oxyview provides a substantial savings as a result of decreasing the number of service calls for the home (DME) provider. Oxyview is a pneumatic metering device that displays oxygen flow near the patient. The Oxyview flow meter easily and quickly installs on to the oxygen tubing nearest the patient where oxygen flow matters the most. Without the Oxyview, patients cannot confirm oxygen flow, and as a result there is an increase in anxiety and the patient calls the home (DME) provider with concerns. Oxyview also allows the home (DME) provider to trouble-shoot other equipment problems over the telephone which eliminates an on-site visit with the patient. More important, the Oxyview provides the patient with more assurance that they are receiving adequate and prescribed oxygen flow. The Oxyview cost less than a single service call.
Ingen Technologies,Inc. - Home
ISO - International Organization for Standardization
Medical Device Consultants for QA & RA, CE Mark, FDA 510k, FDA GMP & ISO 13485
The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Contact:
Ingen Technologies, Inc.
Chris Wirth
909-790-7180
info@ingen-tech.com
Ingen Technologies,Inc. - Home
All my signatures are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on.
-
Ignt news
Ingen Takes Next Step With ISO 13485 Certification for China, Japan, Canada and Europe
On Wednesday June 10, 2009, 3:25 pm EDT
YUCAIPA, Calif., June 10, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the company has commenced ISO 13485 staff training this week with the Emergo Group.
The company has signed contracts with the Austin-Texas based Emergo Group to prepare, train and coordinate all International Standard Organization (ISO) 13485 certifications to market and sell Oxyview in China, Japan, Canada and the European Community. In addition to the ISO certification requirement, the contracts also include the CE Mark required to sell Oxyview in Europe.
The training and document specialist with the Emergo Group, Cheryl Fisher, has been training the Ingen management and staff on ISO certification and document requirement procedures. The ISO certification process will take approximately 3-6 months. ISO is a network of the national standards institutes of 161 countries, one member per country, with a Central Secretariat in Geneva, Switzerland, that coordinates the system. ISO is a non-governmental organization that forms a bridge between the public and private sectors. On the one hand, many of its member institutes are part of the governmental structure of their countries, or are mandated by their government. On the other hand, other members have their roots uniquely in the private sector, having been set up by national partnerships of industry associations. Therefore, ISO enables a consensus to be reached on solutions that meet both the requirements of business and the broader needs of society.
"Ingen has invested tens of thousands of dollars with the Emergo Group to insure ISO 13485 certification in countries that have a strong interest and large revenue potential for our Oxyview product, inclusive of our new Oxyview-Cannula product being introduced in the next week," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
About Oxyview:
Oxyview is a proprietary medical device with U.S. issued patents that stands alone in an increasing patient home oxygen therapy market while there are 23 million patients diagnosed with chronic obstructive pulmonary disease (COPD) in the United States, according to the World Health Organization, and another 12 million patients that are undiagnosed in the U.S. COPD is the fifth leading cause of death in the U.S. and there are 600 million COPD patients worldwide where in most cases, COPD is either the first or second leading cause of death in other countries. The majority of COPD patients require continued home oxygen therapy, which includes all of the required equipment supplied by the home (DME) provider. With the new regulations for oxygen reimbursement in the U.S., the home (DME) providers need to cut costs to stay in business. Oxyview provides a substantial savings as a result of decreasing the number of service calls for the home (DME) provider. Oxyview is a pneumatic metering device that displays oxygen flow near the patient. The Oxyview flow meter easily and quickly installs on to the oxygen tubing nearest the patient where oxygen flow matters the most. Without the Oxyview, patients cannot confirm oxygen flow, and as a result there is an increase in anxiety and the patient calls the home (DME) provider with concerns. Oxyview also allows the home (DME) provider to trouble-shoot other equipment problems over the telephone which eliminates an on-site visit with the patient. More important, the Oxyview provides the patient with more assurance that they are receiving adequate and prescribed oxygen flow. The Oxyview cost less than a single service call.
Ingen Technologies,Inc. - Home
ISO - International Organization for Standardization
Medical Device Consultants for QA & RA, CE Mark, FDA 510k, FDA GMP & ISO 13485
The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Contact:
Ingen Technologies, Inc.
Chris Wirth
909-790-7180
info@ingen-tech.com
Ingen Technologies,Inc. - Home
I am not a registered broker and my signatures are of my own opinion. Make your buys and sells as you see fit, never invest more than you can afford to loose.
-
IGNT News
YUCAIPA, Calif., June 12, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the company was notified by Legend Medical Devices that the first production sample product of the Oxyview-Cannula will arrive next week.
Mr. Bill Liang of Legend Medical Devices notified Ingen that the production samples will arrive next week. The company plans on manufacturing an immediate 10,000 Oxyview-Cannula's with first deliveries available for sale before the end of June-2009. The Oxyview is manufactured by Ingen Technologies in California-USA, and bulk product will be sent to China where Legend Medical Devices will attach and package the Oxyview to various nasal-cannulas under the Ingen-Logo and shipped back to Ingen. The company was recently issued patents in China, with pending patents in Europe, Japan, and Canada. This is in addition to the previously issued patents for the USA.
There are a recorded 23 million patients in the U.S. using home oxygen therapy, and all of them, not including hospitalized patients, use several nasal cannula's each month. There are an estimated 600 million patients worldwide that require home oxygen therapy. The current market for the nasal cannula has a cost range of $2-$6 per cannula, and is used for approximately 10 days before disposed. These current cannulas do not include a built-in flow meter. The new disposable Oxyview-Cannula will include the nasal cannula and the Ingen Oxyview flow-meter attached at a cost of $4.75. Typically the nasal cannula is replaced 3-4 times each month because it builds up bacteria and moisture. The average list price for a nasal cannula is $5.75, however. The DME provider is responsible to include the cannula along with the other oxygen equipment reimbursable at a flat monthly rate from Medicare. There are several advantages to using the new Oxyview-Cannula, inclusive of allowing the patient to be assured that they are receiving the prescribed dosage of oxygen where it is needed the most and trouble-shooting equipment problems over the phone with the oxygen supplier preventing an on-site service call. Without the Oxyview-Cannula, patients cannot confirm oxygen flow nearest to them, nor can they actually be assured that the equipment is functioning properly. "The new Oxyview-Cannula should improve home oxygen therapy and decrease costs associated to unnecessary service call," stated Chris Wirth, COO of Ingen Technologies.
The nasal cannula (NC) is a device used to deliver supplemental oxygen to a patient or person in need of extra oxygen. This device consists of a plastic tube which fits behind the ears, and a set of two prongs which are placed in the nostrils. Oxygen flows from these prongs. The nasal cannula is connected to an oxygen tank, a portable oxygen generator, or a wall connection in a hospital via a flow meter. The nasal cannula carries 1-6 liters of oxygen per minute. There are also infant or neonatal nasal cannulas which carry less than one liter per minute; these also have smaller prongs. The oxygen fraction provided to the patient ranges roughly from 24% to 35%. The nasal cannula was invented by Wilfred Jones and patented in 1949 by his employer, BOC.
The company has been selling Oxyview as an individually packaged respiratory product, and has now developed a disposable and more affordable Oxyview flow meter that will be attached and prepackaged to a variety of nasal cannula products for the 23M home oxygen patients in the USA and 600M patients worldwide. The company will sell the new Oxyview-Cannula under the Ingen logo. The potential market size for the new Oxyview-Cannula is a conservative estimate of $200M per year in the U.S. and $150M per year outside the U.S..
"As mentioned in a previous release, the new disposable Oxyview-Cannula should revolutionize the home oxygen therapy market worldwide. There is nothing else in comparison, and Ingen will sell the new nasal cannula at competitive prices starting this month. For the same price, a patient can choose to either have a nasal cannula with or without a flow-meter. I can't imagine that the patient would choose a nasal cannula without the Oxyview included," stated Scott Sand, CEO and Chairman of Ingen Technologies.
About Oxyview:
Oxyview is a proprietary medical device with U.S. issued patents that stands alone in an increasing patient home oxygen therapy market while there are 23 million patients diagnosed with chronic obstructive pulmonary disease (COPD) in the United States, according to the World Health Organization, and another 12 million patients that are undiagnosed in the U.S. COPD is the fifth leading cause of death in the US and there are 600 million COPD patients worldwide where in most cases, COPD is either the first or second leading cause of death in other countries. The majority of COPD patients require continued home oxygen therapy, which includes all of the required equipment supplied by the home (DME) provider. With the new regulations for oxygen reimbursement in the U.S., the home (DME) providers need to cut costs to stay in business. Oxyview provides a substantial savings as a result of decreasing the number of service calls for the home (DME) provider. Oxyview is a pneumatic metering device that displays oxygen flow near the patient. The Oxyview flow meter easily and quickly installs on to the oxygen tubing nearest the patient where oxygen flow matters the most. Without the Oxyview, patients cannot confirm oxygen flow, and as a result there is an increase in anxiety and the patient calls the home (DME) provider with concerns. Oxyview also allows the home (DME) provider to trouble-shoot other equipment problems over the telephone which eliminates an on-site visit with the patient. More important, the Oxyview provides the patient with more assurance that they are receiving adequate and prescribed oxygen flow. The Oxyview costs less than a single service call.
Ingen Technologies,Inc. - Home
The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Contact:
Ingen Technologies, Inc.
Chris Wirth
909-790-7180
info@ingen-tech.com
Ingen Technologies,Inc. - Home
All my signatures are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on.
-
IGNT Video chart
All my signatures are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on.
|
Checking For Related Data... |
View Profile
View Forum Posts
Private Message
Reply With Quote
Posting Permissions
Bookmarks